Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A3 | O15427 | 1/20 | 0.39 |
| ▸ | F2RL3 | Q96RI0 | 2/20 | 0.39 |
| ▸ | TLR9 | Q9NR96 | 4/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.38 |
| ▸ | PPARD | Q03181 | 4/20 | 0.37 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.37 |
| ▸ | LPAR5 | Q9H1C0 | 3/20 | 0.37 |
| ▸ | PTGES | O14684 | 2/20 | 0.36 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.35 |
| ▸ | KARS1 | Q15046 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5585673 | 0.93 | F2RL3 (0.41) | SLC16A3F2RL3LPAR1LPAR5PTGES | |
| SCHEMBL5585479 | 0.86 | MAOB (0.41) | F2RL3LPAR1LPAR5PTGESTAS2R14 | |
| SCHEMBL5585550 | 0.76 | MAOB (0.41) | F2RL3PTGES | |
| SCHEMBL5585713 | 0.76 | LPAR1 (0.37) | F2RL3PPARDLPAR1LPAR5PTGES | |
| SCHEMBL5585391 | 0.76 | NR4A2 (0.42) | F2RL3HDAC6 | |
| SCHEMBL5999790 | 0.75 | MAOB (0.42) | F2RL3PPARGPPARA | |
| SCHEMBL5585379 | 0.75 | F2RL3 (0.38) | F2RL3PPARDPTGESTAS2R14HDAC6 | |
| SCHEMBL5585491 | 0.74 | MEN1 (0.40) | LPAR1LPAR5PTGESTAS2R14 | |
| SCHEMBL5585511 | 0.72 | MAOB (0.41) | F2RL3 | |
| SCHEMBL5585505 | 0.71 | SRD5A2 (0.38) | F2RL3TLR9PPARDPTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7163952-B2 | Azole compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2007-01-16 | — | — | US | disclosed |
| US-7163952-B2 | Azole compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2007-01-16 | — | — | US | disclosed |
| US-20050065196-A1 | Azole compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2005-03-24 | — | — | US | disclosed |
| EP-1452530-A1 | AZOLE COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2004-09-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065196-A1 | Azole compound and medicinal use thereof | PTPN7, PTPN1, PTPN5 | SLC16A3 3138/4885F2RL3 1999/4885TLR9 1619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.